Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularizatio
Coronary artery disease (CAD) affects around 1.4 million Australians, and represents one of the most...
We assess hemodynamic, vascular, and hormonal effects of endothelin-1 (ET-1) at pathophysiologic lev...
Acute myocardial infarction (AMI) is accompanied by metabolic and neurohormonal changes that may rel...
AIMS: No-reflow after a primary percutaneous coronary intervention (PCI) is associated with a high i...
Aims: No-reflow after a primary percutaneous coronary intervention (PCI) is associated with a high i...
Introduction. Serum endothelin-1 is increasingly released in acute myocardial infarction, by necroti...
The aim of this study was to investigate the behavior of plasma endothelin-1 (ET-1) in 23 patients w...
Endothelin- 1 (ET- 1) is an extremely potent vasoconstrictor peptide derived from vascular endotheli...
Endothelin is a novel endothelium-derived vasoactive peptide with potent vasoconstrictor action in t...
AbstractObjectives. The aim of this study was to investigate the release kinetics of endothelin afte...
To investigate the origin and pathophysiological role of increased plasma endothelin-1 (endothelin-1...
Endothelin (ET) is an endothelium-derived vasoactive peptide, its possible contribution to myocardia...
AbstractObjective: Endothelin plays a role in the regulation of basal coronary tone. We hypothesized...
AbstractVentricular arrhythmogenesis during acute coronary syndromes is a common cause of sudden car...
Endothelin has been implicated in the pathogenesis of ischemic heart disease and congestive heart fa...
Coronary artery disease (CAD) affects around 1.4 million Australians, and represents one of the most...
We assess hemodynamic, vascular, and hormonal effects of endothelin-1 (ET-1) at pathophysiologic lev...
Acute myocardial infarction (AMI) is accompanied by metabolic and neurohormonal changes that may rel...
AIMS: No-reflow after a primary percutaneous coronary intervention (PCI) is associated with a high i...
Aims: No-reflow after a primary percutaneous coronary intervention (PCI) is associated with a high i...
Introduction. Serum endothelin-1 is increasingly released in acute myocardial infarction, by necroti...
The aim of this study was to investigate the behavior of plasma endothelin-1 (ET-1) in 23 patients w...
Endothelin- 1 (ET- 1) is an extremely potent vasoconstrictor peptide derived from vascular endotheli...
Endothelin is a novel endothelium-derived vasoactive peptide with potent vasoconstrictor action in t...
AbstractObjectives. The aim of this study was to investigate the release kinetics of endothelin afte...
To investigate the origin and pathophysiological role of increased plasma endothelin-1 (endothelin-1...
Endothelin (ET) is an endothelium-derived vasoactive peptide, its possible contribution to myocardia...
AbstractObjective: Endothelin plays a role in the regulation of basal coronary tone. We hypothesized...
AbstractVentricular arrhythmogenesis during acute coronary syndromes is a common cause of sudden car...
Endothelin has been implicated in the pathogenesis of ischemic heart disease and congestive heart fa...
Coronary artery disease (CAD) affects around 1.4 million Australians, and represents one of the most...
We assess hemodynamic, vascular, and hormonal effects of endothelin-1 (ET-1) at pathophysiologic lev...
Acute myocardial infarction (AMI) is accompanied by metabolic and neurohormonal changes that may rel...
DOI
Add to ORKG